NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/28/2026
Back to search
Official data from USPTO
MB MAINLINE BIOSCIENCES
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
51
Latest update
04/28/2026
Trademark type
Combined
Nice classes
5
Filing date
11/18/2022
Registration date
04/28/2026
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
04/28/2026
Last transaction
04/28/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
02/01/2025
First use in commerce
02/01/2025
Drawing code
3
Owner type
16
Owner location
Lingang, Shanghai, CN
Examiner
TOOLEY, DAVID E
Law office
N70
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a stylized blue "M" to the left of a stylized light blue "B" above the stylized blue wording "MAINLINE BIOSCIENCE" above stylized blue Asian characters.
Holders and representatives
Holders
Mainline Biosciences (Shanghai) Co., Ltd.
Representatives
Don D. Cha HDC INTELLECTUAL PROPERTY LAW, LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the prevention of cancer or tumor; Pharmaceutical preparations for the treatment and prevention of cancer or tumor; Pharmaceutical preparations for the treatment of cancer or tumor; Pharmaceutical preparations for cancer or tumor; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of cancer; Therapeutic pharmaceutical for the treatment of cancer or tumor
Publications
History of USPTO decisions and trademark events.
51 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
04/28/2026
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/06/2026
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
04/06/2026
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
03/03/2026
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
03/03/2026
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
03/02/2026
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
12/01/2025
GNRT
NON-FINAL ACTION E-MAILED
12/01/2025
CNRT
SU - NON-FINAL ACTION - WRITTEN
12/01/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/14/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/14/2025
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
10/07/2025
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
07/07/2025
GNRT
NON-FINAL ACTION E-MAILED
07/07/2025
CNRT
SU - NON-FINAL ACTION - WRITTEN
07/07/2025
SUPC
STATEMENT OF USE PROCESSING COMPLETE
05/30/2025
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
05/30/2025
IUAF
USE AMENDMENT FILED
03/07/2025
EISU
TEAS STATEMENT OF USE RECEIVED
03/07/2025
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
01/07/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/26/2024
PUBO
PUBLISHED FOR OPPOSITION
11/26/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
11/20/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/29/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
10/29/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
10/29/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
10/29/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
10/29/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/24/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/24/2024
ALIE
ASSIGNED TO LIE
10/24/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
07/17/2024
NREV
NOTICE OF REVIVAL - E-MAILED
07/17/2024
PETG
PETITION TO REVIVE-GRANTED
07/17/2024
PROA
TEAS PETITION TO REVIVE RECEIVED
07/17/2024
XELG
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
04/11/2024
XELR
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
04/11/2024
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
01/11/2024
GNRT
NON-FINAL ACTION E-MAILED
01/11/2024
CNRT
NON-FINAL ACTION WRITTEN
01/11/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/01/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/01/2023
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
09/01/2023
GNRT
NON-FINAL ACTION E-MAILED
09/01/2023
CNRT
NON-FINAL ACTION WRITTEN
09/01/2023
DOCK
ASSIGNED TO EXAMINER
08/30/2023
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
12/10/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/09/2022
NWAP
NEW APPLICATION ENTERED
11/22/2022
Continuous trademark protection
Get notified about every new filing that threatens MB MAINLINE BIOSCIENCES or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.